Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.A234215, A234220 This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.A234215, A234220 Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels.A234220 It has also been observed to be efficacious independent of food intake.A234220
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Amphetamine | Tegoprazan can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Atazanavir | Tegoprazan can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bosutinib | Tegoprazan can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Tegoprazan. |
| Dabigatran etexilate | Tegoprazan can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | Tegoprazan can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Tegoprazan can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Tegoprazan can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dextroamphetamine | Tegoprazan can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Erlotinib | Tegoprazan can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fluconazole | The metabolism of Tegoprazan can be decreased when combined with Fluconazole. |
| Gefitinib | Tegoprazan can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Indinavir | Tegoprazan can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Tegoprazan can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Tegoprazan can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methotrexate | The excretion of Methotrexate can be decreased when combined with Tegoprazan. |
| Methylphenidate | Tegoprazan can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Dexmethylphenidate | Tegoprazan can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Nelfinavir | The serum concentration of Nelfinavir can be decreased when it is combined with Tegoprazan. |
| Nilotinib | The serum concentration of Nilotinib can be decreased when it is combined with Tegoprazan. |
| Pazopanib | Tegoprazan can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Posaconazole | Tegoprazan can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Tegoprazan can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Rilpivirine | Tegoprazan can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Tegoprazan can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Risedronic acid | Tegoprazan can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Saquinavir | The serum concentration of Saquinavir can be increased when it is combined with Tegoprazan. |
| Voriconazole | The metabolism of Tegoprazan can be decreased when combined with Voriconazole. |
| Levothyroxine | Tegoprazan can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Clopidogrel | The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Tegoprazan resulting in a loss in efficacy. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Tegoprazan. |
| Captopril | Tegoprazan can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Tegoprazan. |
| Rifampin | Tegoprazan can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Memantine | Tegoprazan may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Tegoprazan. |
| Mesalazine | Tegoprazan can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolate mofetil | Tegoprazan can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | Tegoprazan can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Tegoprazan. |
| Alendronic acid | The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Tegoprazan. |
| Ibandronate | The therapeutic efficacy of Ibandronate can be decreased when used in combination with Tegoprazan. |
| Clodronic acid | The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Tegoprazan. |
| Etidronic acid | The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Tegoprazan. |
| Tiludronic acid | The therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Tegoprazan. |
| Incadronic acid | The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Tegoprazan. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Tegoprazan. |
| Ketoconazole | Tegoprazan can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tacrolimus | The metabolism of Tacrolimus can be decreased when combined with Tegoprazan. |
| Methenamine | The therapeutic efficacy of Methenamine can be decreased when used in combination with Tegoprazan. |
| Iron Dextran | Tegoprazan can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron | Tegoprazan can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prussian blue | Tegoprazan can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron sucrose | Tegoprazan can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric pyrophosphate | Tegoprazan can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric ammonium citrate | Tegoprazan can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxsil | Tegoprazan can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxides | Tegoprazan can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric sulfate | Tegoprazan can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous bisglycinate | Tegoprazan can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gleptoferron | Tegoprazan can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perflubutane | Tegoprazan can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous sulfate anhydrous | Tegoprazan can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium feredetate | Tegoprazan can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric hydroxide | Tegoprazan can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric cation | Tegoprazan can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous gluconate | Tegoprazan can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous succinate | Tegoprazan can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous fumarate | Tegoprazan can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetraferric tricitrate decahydrate | Tegoprazan can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric oxyhydroxide | Tegoprazan can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric maltol | Tegoprazan can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron polymaltose | Tegoprazan can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dacomitinib | Tegoprazan can cause a decrease in the absorption of Dacomitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ritonavir | Tegoprazan can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Amprenavir | Tegoprazan can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tipranavir | Tegoprazan can cause a decrease in the absorption of Tipranavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Darunavir | Tegoprazan can cause a decrease in the absorption of Darunavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fosamprenavir | Tegoprazan can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lopinavir | Tegoprazan can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Asunaprevir | Tegoprazan can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| TMC-310911 | Tegoprazan can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Palbociclib | The absorption of Palbociclib can be decreased when combined with Tegoprazan. |
| Pexidartinib | The serum concentration of Pexidartinib can be decreased when it is combined with Tegoprazan. |
| Budesonide | Tegoprazan can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Selpercatinib | The serum concentration of Selpercatinib can be decreased when it is combined with Tegoprazan. |
| Octreotide | Tegoprazan can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Doxycycline | Tegoprazan can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sotorasib | The therapeutic efficacy of Sotorasib can be decreased when used in combination with Tegoprazan. |
| Infigratinib | The serum concentration of Infigratinib can be decreased when it is combined with Tegoprazan. |
| Belumosudil | The serum concentration of Belumosudil can be decreased when it is combined with Tegoprazan. |
| Levoketoconazole | Tegoprazan can cause a decrease in the absorption of Levoketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sparsentan | The therapeutic efficacy of Sparsentan can be decreased when used in combination with Tegoprazan. |
| Nirogacestat | The serum concentration of Nirogacestat can be decreased when it is combined with Tegoprazan. |